▲ Peaking
Business
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics faces investor investigations and biotech sector scrutiny ahead of an anticipated August decision.
Capricor Therapeutics
2 trends tracked about this subject — the full history, oldest to newest below.
↑ Rising
Business
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
FDA scientists are disputing efficacy claims regarding Capricor Therapeutics' Phase 3 Duchenne muscular dystrophy cell therapy, triggering a stock plunge.